Skip to content
ChickenStockChickenStock
Research041830
InBody logo

InBody (041830) stock

KOSDAQ · Health Care Equipment & Supplies

KRW 40,750+5.03%(+1,950)

As of Nov 16, 1:21 PM KST

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

11.80x

P/B

1.59x

P/S

2.08x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 73.3 billionKRW 17.7 billionKRW 14.5 billion+30.4%
Q1 2026Consolidated · Filed May 14, 2026KRW 68.4 billionKRW 13 billionKRW 16.3 billion+23.1%
Q4 2025Consolidated · Filed Mar 18, 2026KRW 62.4 billionKRW 9.5 billionKRW 6.4 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 59.8 billionKRW 9.8 billionKRW 9.4 billion+17.9%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 56.2 billionKRW 10.4 billionKRW 7.4 billion+11.8%
Q1 2025Consolidated · Filed May 15, 2025KRW 55.6 billionKRW 7 billionKRW 6.8 billion+14.8%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 18, 2026KRW 233.9 billionKRW 36.8 billionKRW 30 billion—
FY2024Consolidated · Filed Mar 17, 2025KRW 204.5 billionKRW 36.7 billionKRW 32.7 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
12.78%
Of trading value on Nov 13, 2026
Short-sale value
KRW 360 million
Previous 20-day average 7.12%
Net short position
18,430 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
417,665 shares
As of Nov 13, 2026 · 3.10% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 202612.78%KRW 360 million
Nov 12, 20264.38%KRW 120 million
Nov 11, 20268.64%KRW 470 million
Nov 10, 20267.20%KRW 360 million
Nov 9, 20260.20%KRW 10 million
Nov 6, 20260.01%KRW 0
Nov 5, 20265.23%KRW 1.95 billion
Nov 4, 202613.21%KRW 360 million
Nov 3, 202615.58%KRW 440 million
Nov 2, 20260.44%KRW 10 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

InBody (041830) stock information

KOSDAQ

InBody (041830) is listed on KOSDAQ. Its market capitalization is about KRW 549.3 billion. On trailing-twelve-month earnings the P/E ratio is 11.8, and the P/B ratio is 1.59. Return on equity is 13.4%. These figures are computed in-house from official filings and are reference information only.

InBody — frequently asked questions

What is the P/E ratio of InBody (041830)?
On a trailing-twelve-month basis, 041830 trades at a P/E ratio of 11.8. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of InBody?
041830 has a market capitalization of about KRW 549.3 billion. The figure moves with the share price and is refreshed each trading day.
Does InBody pay a dividend?
041830 has a dividend yield of about 1.47%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.